We retrospectively investigated whether perampanel (PER) could serve as an alternative for treating drug-resistant seizures in lissencephaly. We investigated the following data: age at onset of epilepsy, age at start of PER, aetiology, brain MRI findings, seizure type, seizure frequency, adverse effects, and concomitant anti-epileptic drugs. There were 5 patients with lissencephaly, including 2 with Miller-Dieker syndrome. Four out of five patients exhibited ≥50% seizure reduction. Myoclonic seizures disappeared in 1 patient. PER was an effective adjunctive anti-seizure drug in our series of patients with lissencephaly.
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Introduction
Alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA 1 )
receptors have long been suggested to play an important role in ictogenesis and epileptogenesis [1] . Perampanel (PER) is a selective noncompetitive AMPA receptor antagonist that was developed for the treatment of epilepsy.
PER does not inhibit N-methyl-D-aspartate (NMDA) receptors, a different class of ionotropic glutamate receptors. Recently, it has been reported effective for the treatment of various epileptic disorders, including Lennox-Gastaut syndrome; it has been effective for treatment of myoclonic seizures, such as progressive myoclonus epilepsy; Lafora disease [2] , dentatorubral-pallidoluysian atrophy (DRPLA) [3] and Unverricht-Lundborg disease [4] .
Neuronal migration disorders include lissencephaly, pachygyria, subcortical band heterotopia (SBH), and periventricular nodular heterotopias, which are rare brain malformations caused by defective neuronal migration during embryonic development. Complete cortical 1 Abbreviations: AMPA, alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid;
DRPLA, dentatorubral-pallidoluysian atrophy; GTCS, generalized tonic-clonic seizures;
NMDA, N-methyl-D-aspartate; PER, perampanel
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A C C E P T E D M A N U S C R I P T 5 disorganization results in lissencephaly, which typically manifests with drug-resistant epilepsy. Seizures occur in >90% of children; most children have multiple seizure types including persisting spasms, focal seizures, tonic seizures, and atonic seizures [5] . Most cases of daily seizures are a burden to both patients and caregivers; they commonly fail to exhibit seizure control, despite the use of many anti-seizure drugs for the resolution of seizures [6] .
We retrospectively investigated whether PER could serve as an alternative for treating drug-resistant seizures in lissencephaly.
Case Report
We retrospectively surveyed patients with lissencephaly who were treated with PER at the Saitama Children's Medical Center from 2016 to 2018. A total of 5 patients (4 boys, 1 girls) were included in this study. We retrospectively collected the following clinical data: age at the onset of epilepsy, age at the start of PER, aetiology, brain magnetic resonance imaging (MRI) findings, seizure types, seizure frequency before and after PER administration, adverse effects, and concomitant anti-seizure drugs used at the start of PER. PER was administered at 0.04 mg/kg/day, and was
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A C C E P T E D M A N U S C R I P T 6 increased at 2-4-week intervals. In this study, drug efficacy was defined as ≥50% seizure reduction rate at 3 months from the start of PER. Seizure frequency was observed by caregivers in daily life and finally assessed by a paediatric epileptologist.
Since 2016, PER has been approved for use in Japan in patients with epilepsy who are >12 years of age; it can be used for the adjunctive treatment Clinical data of 5 patients with lissencephaly are shown in Table 1 .
The median age at onset of epilepsy was 2 months (range: 1 month-6 months). Median age at the start of PER was 7 years, 4 months (range: 2 years, 6 months-16 years, 1 month). Five patients with lissencephaly 
Discussion
In this retrospective cohort study, PER was effective in the treatment of patients with lissencephaly. A 50% responder rate (50% RR; i.e., at least 50% seizure reduction upon administration of PER) of PER was observed in 4 of 5 patients (80.0%) in our study. A prior study reported that the efficacy (50% responder rate) of PER in patients with primary GTCS was 64.2% [7] .
Patients with lissencephaly typically exhibit drug-resistant daily seizures. It is important to consider the mechanism by which PER is effective for the treatment of neuronal migrating disorders. Many reports have surveyed neuronal migration, which is affected by a variety of factors [8] .
Glutamate plays an essential role in neuronal migration. Glutamate receptors consist of ionotropic receptors: NMDA, AMPA, kainic, and metabolic receptors. AMPA receptors, but not NMDA receptors, are involved in neuronal migration. AMPA receptors play a key role in neuronal migration [9] . Functional AMPA receptors are reportedly expressed by tangentially migrating interneurons in the developing brain, while metabotropic glutamate receptor primarily appears in radial glial cells [10] . Neurons A limitation of this study is the small number of patients. Neural migration disorders are relatively rare. In addition, evaluation of anti-seizure drugs was limited to the subjective assessments of seizure frequency dependent on observations by caregivers. Moreover, the mechanism underlying the effectiveness of PER for lissencephaly-associated epilepsy is unknown. Therefore, our study findings are not suitably definitive, and we speculate that PER may be effective.
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In conclusion, PER was an effective adjunctive anti-seizure drug in our series of patients with lissencephaly. 
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